U.S. markets close in 4 hours 40 minutes
  • S&P 500

    3,990.73
    -35.39 (-0.88%)
     
  • Dow 30

    34,089.97
    -257.06 (-0.75%)
     
  • Nasdaq

    11,134.61
    -91.75 (-0.82%)
     
  • Russell 2000

    1,849.01
    -20.18 (-1.08%)
     
  • Crude Oil

    75.87
    -0.41 (-0.54%)
     
  • Gold

    1,741.90
    -12.10 (-0.69%)
     
  • Silver

    20.90
    -0.53 (-2.50%)
     
  • EUR/USD

    1.0386
    -0.0018 (-0.18%)
     
  • 10-Yr Bond

    3.6790
    -0.0120 (-0.33%)
     
  • GBP/USD

    1.2026
    -0.0065 (-0.54%)
     
  • USD/JPY

    138.7890
    -0.3110 (-0.22%)
     
  • BTC-USD

    16,094.70
    -479.96 (-2.90%)
     
  • CMC Crypto 200

    376.96
    -3.33 (-0.88%)
     
  • FTSE 100

    7,487.92
    +1.25 (+0.02%)
     
  • Nikkei 225

    28,162.83
    -120.20 (-0.42%)
     

Need To Know: The Consensus Just Cut Its Chinook Therapeutics, Inc. (NASDAQ:KDNY) Estimates For 2022

Today is shaping up negative for Chinook Therapeutics, Inc. (NASDAQ:KDNY) shareholders, with the analysts delivering a substantial negative revision to this year's forecasts. This report focused on revenue estimates, and it looks as though the consensus view of the business has become substantially more conservative.

Following the latest downgrade, the seven analysts covering Chinook Therapeutics provided consensus estimates of US$3.1m revenue in 2022, which would reflect a painful 94% decline on its sales over the past 12 months. Per-share losses are expected to explode, reaching US$2.45 per share. Yet prior to the latest estimates, the analysts had been forecasting revenues of US$3.7m and losses of US$2.27 per share in 2022. So there's been quite a change-up of views after the recent consensus updates, with the analysts making a serious cut to their revenue forecasts while also expecting losses per share to increase.

Check out our latest analysis for Chinook Therapeutics

earnings-and-revenue-growth
earnings-and-revenue-growth

Taking a look at the bigger picture now, one of the ways we can understand these forecasts is to see how they compare to both past performance and industry growth estimates. These estimates imply that sales are expected to slow, with a forecast annualised revenue decline of 100% by the end of 2022. This indicates a significant reduction from annual growth of 4,385% over the last year. By contrast, our data suggests that other companies (with analyst coverage) in the same industry are forecast to see their revenue grow 15% annually for the foreseeable future. It's pretty clear that Chinook Therapeutics' revenues are expected to perform substantially worse than the wider industry.

The Bottom Line

The most important thing to note from this downgrade is that the consensus increased its forecast losses this year, suggesting all may not be well at Chinook Therapeutics. Unfortunately analysts also downgraded their revenue estimates, and industry data suggests that Chinook Therapeutics' revenues are expected to grow slower than the wider market. Often, one downgrade can set off a daisy-chain of cuts, especially if an industry is in decline. So we wouldn't be surprised if the market became a lot more cautious on Chinook Therapeutics after today.

Even so, the longer term trajectory of the business is much more important for the value creation of shareholders. At Simply Wall St, we have a full range of analyst estimates for Chinook Therapeutics going out to 2024, and you can see them free on our platform here.

Another way to search for interesting companies that could be reaching an inflection point is to track whether management are buying or selling, with our free list of growing companies that insiders are buying.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Join A Paid User Research Session
You’ll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself. Sign up here